Cytosorbents Corporation · NASDAQ:CTSO
Cytosorbents — Investor Presentation (June 2010)
5 slides from Cytosorbents's investor presentation, Jun 29, 2010
Slide 1: CytoSorbents
CytoSorbents.. CytoSorbents CYTOSORBENTS CORPORATION (OTCBB: CTSO) is a ciitcal-care focused therapeutic device company in clinical trials with a powerful purification technology based on biocompatible, UNE SNe highly porous polymer beads designed to actively remove disease-causing substances from b
Slide 2: CytoSorb is the cornerstone of our critical care strategy
CYTOSORB™ IS THE CORNERSTONE OF OUR CRITICAL CARE STRATEGY. CytoSorb™ is a unique, biocompatible cytokine fter that has the potential to broadly reduce cytokine storm without compromising the integrity of the immune system. Cytokines are small proteins that, in moderation, help to stimulate and regu
Slide 3: European Sepsis Trial and CytoSorb commercialization strategy
CYTOSORBENTS IS CURRENTLY CONDUCTING ITS EUROPEAN SEPSIS TRIAL, a 14-site, randomized, contrlled clinical trial in Germany using CytoSorb™ to treat up to 100 patients with severe sepsis in the setting of respiratory failure. Patients are treated dally for up to seven days. Endpoints include cytokine
Slide 4: CytoSorbents' patent portfolio is strong and growing
CYTOSORBENTS’ PATENT PORTFOLIO IS STRONG AND GROWING with 27 issued patents and multiple applications pending. These patents establish CytoSorbents as one ofthe leaders in extracorporeal blood purification to remove toxins and cytokines from blood and physiologic fuids. The patents, all of which hav
Slide 5: Business Development Strategy
BUSINESS DEVELOPMENT STRATEGY GyloSorbents has an active business development program, seeking potential strategic partners to license various potential applications of our technology, help fund clinical development and assist inthe sales, marketing and distribution of CytoSorb™ in various geographi